Verona Pharma Share Discussion Threads

[bonzo] 07/9/2017 09:01

Good to see some positive movement again. Trial results look very encouraging.

[timbo003] 07/9/2017 07:56

Presentation slides for today's webcast now available:

[timbo003] 07/9/2017 07:47

>>bewise

Indeed

I think VRP have previously demonstrated an additive effect with a SAMA, but now they have demonstrated an additive effect with a LAMA (twice a day dosing). A nice clean result and it adds further support for the 6mg dose (rather than a lower dose)

[bewise2] 07/9/2017 07:31

Rns: excellant news today :)

[shakin not stirred] 05/9/2017 23:47

PHOWDO on what assumption do you base that . Have you had experience of Stifel as a broker and Nomad before and can you divulge further evidence to your remark. I have no knowledge of them. Cheers

[insideryou] 05/9/2017 09:45

AS per usual

[phowdo] 05/9/2017 09:01

Stifel as broker and nomad = shareholders get stiffed.

[haff1] 05/9/2017 08:40

Whoops whats this all about?

[shearluc] 30/8/2017 10:29

50 000 @£1.24 Trade code 'OK' = ordinary trade with delayed publication requested. MMs have dropped the bid but that could be a buy? Any thoughts?

[bewise2] 21/8/2017 13:47

Verona Pharma

21 Aug 2017 10:41:48

Verona Pharma plc

LONDON, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 122.5 pence per Ordinary Share.  Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company's issued share capital.

[gersemi] 09/8/2017 18:26

Tip Update: Buy at 119p @ 9 Aug 2017

Tip style
SPECULATIVE
Risk rating
HIGH
Timescale
LONG TERM

Our previous tip
We said BUY at 175p (adjusted for 50:1 share consolidation) on 22 Sep 2016
Tip performance to date
-32%

By Megan Boxall

Verona Pharma’s (VRP) busy six months of drug development has come at a cost to the bottom line. A spike in research and development expenditure in the six months to June 2017 widened operating losses from £1.9m to £10.9m. But an increase in shares in issue meant losses per share were softer at 7.3p, compared with 8.7p in 2016.

As biotechnology companies go, there is a lot to like about Verona. Its novel respiratory drug, RPL554, is undergoing several different clinical trials including two studies in Europe: one to assess appropriate dosing and one in combination with another regularly used respiratory drug. There is also an early-stage study in the US. Meanwhile, the net cash balance is healthy at £95m thanks to the group’s recent Nasdaq IPO.

IC View

Verona is making steady progress in an exciting part of the respiratory market and given its healthy pile of cash, we see no reason – aside from the risk of further fundraising, which looks remote – to change our buy call, at 119p. Buy.

Last IC View: Buy, 133p, 2 May 2017

[haff1] 26/7/2017 16:26

...and no effect on share price ..

[haff1] 25/7/2017 15:18

..this has been jam tomorrow for so so long and constantly wilting in share price Hopefully it will one day show some lasting upward trend?

[bewise2] 23/7/2017 09:51

Just noticed this from a RNS back in April....hopefully things will be on the up in 2018.......




Joe Anderson, Chief Executive Officer of Arix Bioscience Plc, commented:"Verona is a dynamic company with an important drug asset, which we believe has the potential to address significant unmet needs in respiratory medicine.  RPL554 has shown potential in COPD and cystic fibrosis. This authorisation by the FDA puts it on a path towards advancing this promising candidate towards approval."

 

[bewise2] 27/6/2017 08:30

Dose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today regulatory approval in five European countries, comprising the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic, for a Phase 2b dose-ranging trial of RPL554 for maintenance treatment of chronic obstructive pulmonary disease (COPD). The trial is expected to commence in the third quarter of 2017, with top-line data expected in the second half of 2018.

[bewise2] 23/6/2017 17:37

Anybody intending to go to the shareholders meeting next week?

[kwizza] 23/6/2017 08:31

Is this a new low for the share price

[ewads] 23/6/2017 08:10

American adventure turned sour?